Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 84

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Chelohart® ods of treatment, were prescribed a course of CHELOHART®, 1 capsule 2 times a day with meals for 30 days. The control group consisted of 10 patients (6 men aged 47 to 66 years and 4 women aged 50 to 69 years) who were prescribed only conventional treatment: long-acting nitrates, β-blockers, corinfar, corvalol, motherwort tincture, and other sedatives (2, 3). RESEARCH METHODS The study of the effectiveness of the use of CHELOHART® was carried out based on generally accept- ed research methods. Patients’ complaints were assessed in dynamics, general clinical and biochemical blood tests, ultrasound examination of the heart, electrocardiography, a dosed exercise test on a bicycle ergometer were carried out according to the method of step-by-step increasing intermittent activity. RESEARCH RESULTS The study results of the dynamics of changes in subjective indicators showed that in patients taking CHELOHART®, the number of complaints about the general condition, shortness of breath, recurring pain in the heart, and a feeling of rapid heartbeat decreased. The frequency and duration of angina attacks significantly reduced. In 56% of patients, it was possible to reduce by half the daily dose of nitrates of prolonged action against the background of a persistent decrease in the attacks of chest pain in comparison with the initial level before treatment (Table 1). Dynamics of subjective indicators in patients with coronary heart disease. Table 1 Complaints Patient Groups After treatment with conventional means, After treatment with CHELOHART®, abs. (%) abs. (%) Improvement Without Improvement Without Improvements Improvements Recurrent pain in the heart region 4 (40%) 6 (60%) 15 (68,2%)* 7 (31,8%)* Dyspnea 6 (60%) 4 (40%) 16 (72,7%)* 6 (27,3%)* Weakness 7 (70%) 3 (30%) 16 (72,7%)* 6 (27,3%)* Dizziness 6 (60%) 4 (40%) 12 (54,5%) 10 (45,5%) Headaches 5 (50%) 5 (50%) 15 (68,2%)* 7 (31,8%)* Noise in ears 5 (50%) 5 (50%) 14 (63,6%) 8 (36,4%) Palpitations 6 (60%) 4 (40%) 17 (77,3%)* 5 (22,7%)* * p <0.05 compared with the indicator in patients after treatment with conventional means. The study of the dynamics of changes in mineral metabolism showed that in patients of both groups, the potassium content in the blood plasma and calcium in the blood serum increased, approaching normal values. There was no significant difference in indicators in patients of the primary and control groups. However, the indicators after treatment were better in patients of the primary group who took CHELOHART®than in patients in the control group. The magnesium content in the blood serum re- mained within the normal range before and after treatment in patients of both groups (Table 2).

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.